FDA Drug & Cosmetic Labeling Compliance: A Complete Guide for US Market Entry (2026)

Labeling errors are the number one reason FDA issues import alerts, warning letters, and detention notices to foreign manufacturers. Whether you are exporting prescription drugs, OTC medications, dietary supplements, or herbal cosmetics to the United States, your labels must meet strict FDA requirements before your products can legally enter the US market.

This guide explains the FDA labeling compliance requirements for drugs, OTC products, and cosmetics — including special considerations for herbal cosmetics — and outlines the most common mistakes that get products rejected at the US border.

Why FDA Labeling Compliance Matters

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a product is considered 'misbranded' if its label fails to meet FDA requirements. Misbranding is a federal violation with serious consequences: FDA can detain your shipment at the port of entry, issue a warning letter with a mandatory public disclosure on the FDA website, initiate a mandatory product recall, and pursue civil or criminal penalties.

FDA Drug Labeling Requirements: What Must Be on Every Drug Label

All drug products sold in the United States — whether prescription (Rx) or over-the-counter (OTC) — must carry an FDA-compliant label. The following are mandatory elements for drug labels:

• Established name of the drug (generic name) and brand name, if applicable

• Net quantity of contents (weight, measure, or numerical count)

• Name and address of the manufacturer, packer, or distributor

• National Drug Code (NDC) number in the correct FDA NDC format

• Lot or batch number for traceability

• Expiration date in the correct format (MM/YYYY or MM/DD/YYYY)

• Storage conditions and any required warnings

• Adequate directions for use (or reference to a package insert for Rx drugs)

OTC Drug Labeling: The Drug Facts Panel

Over-the-counter (OTC) drugs in the US are required to display a standardized Drug Facts panel as specified in 21 CFR Part 201.66. The Drug Facts panel must include, in this exact order: Active Ingredients with their purposes; Uses (indications); Warnings (including 'Keep out of reach of children'); Directions for use; Other information; and Inactive Ingredients. The font size, layout, contrast ratio, and terminology must all comply with FDA specifications. A poorly formatted Drug Facts panel is one of the most common reasons OTC products are flagged at import.

FDA Labeling for Herbal Cosmetics: A Special Compliance Challenge

Herbal cosmetics occupy a uniquely complex regulatory space in the USA. A product may be classified as a cosmetic, a drug, or both — depending on its intended use and marketing claims. This distinction is critical because drugs and cosmetics face very different labeling requirements.

A product is regulated as a drug if it makes therapeutic or physiological claims (e.g., 'relieves pain', 'treats acne', 'prevents hair loss'). The same product without such claims may be regulated only as a cosmetic. Many herbal and Ayurvedic products from India, China, and Southeast Asia are marketed with therapeutic claims that automatically trigger FDA drug regulations, requiring an OTC monograph or NDA approval before US sale.

Key labeling requirements for herbal cosmetics include:

• Ingredient list using INCI names in descending order of predominance (cosmetic requirement under MoCRA)

• No unapproved drug claims — avoid terms like 'heals', 'cures', 'treats', 'prevents disease' unless the product is a registered OTC drug

• No color additives not approved for cosmetic use by the FDA (many natural colorants used in herbal products fall into this category)

• Fragrance allergen disclosure for any of the 26 EU-listed allergens if present above thresholds

• Responsible person contact (US address or phone number)

The 7 Most Common FDA Labeling Mistakes Foreign Manufacturers Make

1. Wrong NDC format: The NDC must appear in one of three FDA-approved configurations (4-4-2, 5-3-2, or 5-4-1). Using a non-standard format causes SPL filing rejection.

2. Missing or incorrect Drug Facts panel: Incorrect order of sections, missing sections, or font sizes below the FDA minimum immediately trigger misbranding.

3. Unapproved drug claims on cosmetics: Any claim implying a physiological effect turns a cosmetic into an unapproved new drug in FDA's view.

4. Missing principal display panel (PDP) information: The product name and net quantity must appear on the PDP with the correct type size relative to the panel area.

5. Incorrect ingredient nomenclature: Drug active ingredients must use USAN (United States Adopted Names), not INN or common herbal names.

6. No US distributor address: Products imported by a foreign manufacturer must show a US distributor name and address, not just the foreign manufacturer's details.

7. Bilingual label issues: Labels in languages other than English must still contain all required English text. Non-English text cannot replace English labeling elements.

How Axentra Global Supports Your FDA Labeling Compliance

Axentra Global's FDA Labeling Review service provides comprehensive label compliance review before your product ships to the US. Our regulatory experts review your drug, OTC, or cosmetic artwork against all applicable FDA regulations, checking NDC format accuracy, Drug Facts panel compliance, claim validation for drugs and cosmetics, INCI ingredient nomenclature, and SPL file preparation for drug listing with the FDA.

A labeling review before submission can prevent costly import detentions, warning letters, and the expense of recalling and relabeling an entire product batch. Contact Axentra today for a fast-turnaround FDA labeling review for your product.